Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lifeward Ltd.LFWD · Entity 7620 | Director | August 01, 2025 | August 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lifeward Ltd.
Report date August 01, 2025 · Filed August 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 1.75 per shareSEC Table I · non-derivative | IndirectESOP | 86,457 |
Reported balance
After 2025-08-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-08-01 · Grant · Acquired 71,839 · Balance 86,457 F1: Represents 71,839 ordinary shares, par value NIS 1.75 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 1, 2025 (the "Grant Date") under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months following the Grant Date. |
| Ordinary Shares, par value NIS 1.75 per shareSEC Table I · non-derivative | Direct | 18,516 |
Reported balance
Holding disclosure · report date 2025-08-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 18,516 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 71,839 ordinary shares, par value NIS 1.75 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 1, 2025 (the "Grant Date") under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months following the Grant Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NxStage Medical, Inc.
Report date February 21, 2019 · Filed February 25, 2019
Section 16 reporting ended · disclosed 2019-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 1
1 source rowRow 1 · 2019-02-21 · Disposition to issuer · Disposed 86,401 · Balance 0 F1: Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 · Expires 2019-03-08 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-21 · Disposition to issuer · Disposed 7,542 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.03 · Expires 2023-03-03 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-21 · Disposition to issuer · Disposed 25,897 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.66 · Expires 2024-03-09 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-21 · Disposition to issuer · Disposed 36,958 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.66 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-21 · Disposition to issuer · Disposed 102,529 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.58 · Expires 2026-03-08 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-21 · Disposition to issuer · Disposed 178,772 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.89 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-21 · Disposition to issuer · Disposed 99,711 · Balance 0 F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-03-09 | Direct | 0 |
Reported balance
After 2019-02-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-21 · Disposition to issuer · Disposed 23,286 · Balance 0 F3: These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash.
F2: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price.
F3: These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2025 Filed Aug 7, 2025 18:11 UTC | Lifeward Ltd. LFWD · Entity 7620 | GrantOrdinary Shares, par value NIS 1.75 per share | 71,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-013870 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · ESOP Disclosed balance after: 86,457 F1 · shares: Represents 71,839 ordinary shares, par value NIS 1.75 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 1, 2025 (the "Grant Date") under the Lifeward Ltd. 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months following the Grant Date. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 08:55 UTC | Lifeward Ltd. LFWD · Entity 7620 | PurchaseOrdinary Shares, par value NIS 1.75 per share | 6,000 | $1.69 | $10,140.00 |
DisclosureSEC source: 0001062993-24-020707 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,516 F1 · shares: Represents Ordinary Shares purchased in the open market on December 13, 2024. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:17 UTC | Lifeward Ltd. LFWD · Entity 7620 | PurchaseOrdinary Shares, par value NIS 1.75 per share | 7,916 | $5.01 | $39,659.16 |
DisclosureSEC source: 0001062993-24-011286 · form4.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,516 F3 · shares: Represents Ordinary Shares purchased in the open market on May 23, 2024. F2 · balance_after: The reported number of shares has been adjusted to reflect the impact of the Issuer's 1-for-7 reverse share split, which became effective on March 15, 2024. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:17 UTC | Lifeward Ltd. LFWD · Entity 7620 | PurchaseOrdinary Shares, par value NIS 1.75 per share | 84 | $5.01 | $420.84 |
DisclosureSEC source: 0001062993-24-011286 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,600 F1 · shares: Represents Ordinary Shares purchased in the open market on May 22, 2024. F2 · balance_after: The reported number of shares has been adjusted to reflect the impact of the Issuer's 1-for-7 reverse share split, which became effective on March 15, 2024. Read SEC document |
| September 13, 2023 Filed Sep 19, 2023 16:38 UTC | Lifeward Ltd. RWLK · Entity 7620 | GrantOrdinary Shares, par value NIS 0.25 per share | 59,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-018266 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · ESOP Disclosed balance after: 102,330 F1 · shares: Represents 59,595 ordinary shares, par value NIS 0.25 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on September 13, 2023 (the "Grant Date") under the ReWalk Robotics Ltd. Amended and Restated 2014 Incentive Compensation Plan. The RSUs vest ratably in four equal quarterly installments starting three months following the Grant Date. Read SEC document |
| September 07, 2023 Filed Sep 7, 2023 16:44 UTC | Lifeward Ltd. RWLK · Entity 7620 | PurchaseOrdinary Shares, par value NIS 0.25 per share | 27,309 | $0.68 | $18,570.12 |
DisclosureSEC source: 0001062993-23-017792 · form4.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,616 F2 · shares: Represents Ordinary Shares purchased in the open market on September 7, 2023. Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 16:44 UTC | Lifeward Ltd. RWLK · Entity 7620 | PurchaseOrdinary Shares, par value NIS 0.25 per share | 30 | $0.68 | $20.40 |
DisclosureSEC source: 0001062993-23-017792 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,307 F1 · shares: Represents Ordinary Shares purchased in the open market on September 6, 2023. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 16:20 UTC | Lifeward Ltd. RWLK · Entity 7620 | PurchaseOrdinary Shares, par value NIS 0.25 per share | 2,661 | $0.68 | $1,809.48 |
DisclosureSEC source: 0001062993-23-017547 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,277 F1 · shares: Represents Ordinary Shares purchased in the open market on September 1, 2023. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 16:44 UTC | Lifeward Ltd. RWLK · Entity 7620 | PurchaseOrdinary Shares, par value NIS 0.25 per share | 1,616 | $0.62 | $993.84 |
DisclosureSEC source: 0001062993-23-017363 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,616 F1 · shares: Represents Ordinary Shares purchased in the open market on August 29, 2023. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 16:03 UTC | Lifeward Ltd. RWLK · Entity 7620 | GrantOrdinary Shares | 42,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-010602 · form4.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · ESOP Disclosed balance after: 42,735 F1 · shares: Represents 42,735 ordinary shares, par value NIS 0.25 per share ("Ordinary Shares"), issuable upon the vesting of restricted stock units ("RSUs") granted on April 20, 2022 under the ReWalk Amended and Restated 2014 Incentive Compensation Plan, in connection with the reporting person's appointment as director effective as of that date. The RSUs vest in four equal quarterly installments starting three months from the date of grant, and may only be settled in Ordinary Shares. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerRestricted Stock Unit · Derivative | 23,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 8 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,286 shares Expires 2020-03-09 F3 · kind: These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 99,711 | $0.00 Strike: $27.89 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 7 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,711 shares Expires 2027-03-08 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 178,772 | $0.00 Strike: $15.58 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 6 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 178,772 shares Expires 2026-03-08 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 102,529 | $0.00 Strike: $16.66 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 5 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,529 shares Expires 2025-03-02 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,958 | $0.00 Strike: $14.66 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 4 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,958 shares Expires 2024-03-09 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,897 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 3 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,897 shares Expires 2023-03-03 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,542 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · derivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,542 shares Expires 2019-03-08 F2 · kind: This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Disposition to issuerCommon Stock | 86,401 | $30.00 | $2,592,030.00 |
DisclosureSEC source: 0001246360-19-000768 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. Read SEC document |
| May 21, 2018 Filed May 21, 2018 15:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,392 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001246360-18-001614 · form.xml · derivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,392 shares Expires 2018-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2018 Filed May 21, 2018 15:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 5,392 | $18.59 | $100,237.28 |
DisclosureSEC source: 0001246360-18-001614 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionRestricted Stock Unit · Derivative | 11,642 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001075 · form.xml · derivative · entry 4 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,286 Underlying: Common Stock · 11,642 shares Expires 2020-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | GrantRestricted Stock Unit · Derivative | 34,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001075 · form.xml · derivative · entry 3 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,928 Underlying: Common Stock · 34,928 shares Expires 2020-03-09 F1 · derivative.exercise_date: Award granted pursuant to the 2017 Performance Share Plan, vesting in 3 equal annual installments beginning March 9, 2018. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Tax withholdingCommon Stock | 3,536 | $24.37 | $86,172.32 |
DisclosureSEC source: 0001246360-18-001075 · form.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,009 Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 11,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001246360-18-001075 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2017 Filed Oct 4, 2017 17:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $27.56 | $27,560.00 |
DisclosureSEC source: 0001246360-17-002901 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 16:07 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $27.95 | $27,950.00 |
DisclosureSEC source: 0001246360-17-002653 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| August 10, 2017 Filed Aug 10, 2017 16:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $29.26 | $29,260.00 |
DisclosureSEC source: 0001246360-17-002559 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,331 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · derivative · entry 10 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,392 Underlying: Common Stock · 2,331 shares Expires 2018-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,669 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · derivative · entry 9 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,542 Underlying: Common Stock · 2,669 shares Expires 2019-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $14.66 | $0.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · derivative · entry 8 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,958 Underlying: Common Stock · 12,000 shares Expires 2024-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · derivative · entry 7 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,897 Underlying: Common Stock · 7,000 shares Expires 2023-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 18,000 | $29.63 | $533,340.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · nonDerivative · entry 6 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 6,000 | $29.66 | $177,960.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · nonDerivative · entry 5 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 2,331 | $18.59 | $43,333.29 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · nonDerivative · entry 4 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 2,669 | $18.48 | $49,323.12 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · nonDerivative · entry 3 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 12,000 | $14.66 | $175,920.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2017 Filed Aug 8, 2017 18:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 7,000 | $11.03 | $77,210.00 |
DisclosureSEC source: 0001246360-17-002524 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:00 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $11.03 | $0.00 |
DisclosureSEC source: 0001246360-17-002506 · form.xml · derivative · entry 3 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,897 Underlying: Common Stock · 7,000 shares Expires 2023-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:00 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 7,000 | $22.98 | $160,860.00 |
DisclosureSEC source: 0001246360-17-002506 · form.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:00 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 7,000 | $11.03 | $77,210.00 |
DisclosureSEC source: 0001246360-17-002506 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 17:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $25.19 | $25,190.00 |
DisclosureSEC source: 0001246360-17-002333 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| June 14, 2017 Filed Jul 7, 2017 17:28 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $23.74 | $23,740.00 |
DisclosureSEC source: 0001246360-17-002332 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,250 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001246360-17-002156 · form.xml · derivative · entry 3 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,723 Underlying: Common Stock · 2,250 shares Expires 2018-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 2,250 | $23.59 | $53,077.50 |
DisclosureSEC source: 0001246360-17-002156 · form.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 16:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 2,250 | $18.59 | $41,827.50 |
DisclosureSEC source: 0001246360-17-002156 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 17:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionStock Option (Right to Buy) · Derivative | 250 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001246360-17-001848 · form.xml · derivative · entry 3 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,973 Underlying: Common Stock · 250 shares Expires 2018-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2017 Filed May 11, 2017 17:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 250 | $23.59 | $5,897.50 |
DisclosureSEC source: 0001246360-17-001848 · form.xml · nonDerivative · entry 2 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| May 10, 2017 Filed May 11, 2017 17:56 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | Exercise / conversionCommon Stock | 250 | $18.59 | $4,647.50 |
DisclosureSEC source: 0001246360-17-001848 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 4, 2017 17:14 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $29.95 | $29,950.00 |
DisclosureSEC source: 0001246360-17-001726 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,903 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 17:35 UTC | NxStage Medical, Inc. NXTM · Entity 159895 | SaleCommon Stock | 1,000 | $26.10 | $26,100.00 |
DisclosureSEC source: 0001246360-17-001594 · form.xml · nonDerivative · entry 1 Turk Joseph E Jr · CIK 0001341403 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,903 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.